Feb 24 2025 38 mins 1
In this episode of From Bench to Fireside, host John Connolly, PhD, Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy (PICI), interviews Antoni Ribas, MD, PhD, Director of the PICI Center at UCLA, professor of medicine at the David Geffen School of Medicine at UCLA and Director of the Tumor Immunology Program at the UCLA Health Jonsson Comprehensive Cancer Center.
Dr. Ribas, who led one of the largest phase 1 clinical oncology trial to date, has been instrumental in advancing our understanding of immune checkpoint inhibitors and cellular therapies. Together, they explore Dr. Ribas' journey from his early work in immunology to his current cutting-edge research in reprogramming immune system cells, discussing overarching trends in patient outcomes and the transformative potential of multiplex trials. They also discuss PICI's collaborative approach to uniting scientists, investors and cell therapies together, Dr. Ribas's perspective on prioritizing scientific advancement over publication, his vision of shifting cancer from a surgical disease to an immunotherapy-treatable condition, his insights on mentoring the next generation of researchers… and more.
--
From Bench to Fireside™ is a new podcast from the Parker Institute for Cancer Immunotherapy (PICI) that takes you from behind the lab bench to the frontiers of cancer research. Each episode features an interview with members of the PICI Network, pioneers in cancer immunotherapy and leaders at world-renowned cancer research institutions. Throughout the conversations, these experts weigh in on the potential of the human immune system to target and eradicate cancer cells, from the latest breakthroughs in immuno-oncology to their impact on patients. Along the way, they unpack the hurdles encountered and the opportunities that lie ahead.
Tune in to hear from scientific leaders who stand at the forefront of developing breakthrough immune therapies with the goal of turning all cancers into curable diseases. From Bench to Fireside™ is produced by the Parker Institute for Cancer Immunotherapy. Follow PICI on LinkedIn, X @parkerici or visit www.parkerici.org.